• Through HealthTab, its flagship offering, Avricore is enabling consumers to access important health information in a convenient way and at a time that is fitting for them
• HealthTab is a turnkey point-of-care testing solution that combines a secure, cloud-based platform with point-of-care technologies
• In a rapidly evolving world of healthcare that has seen consumers become more health-conscious and prompted the adoption of digital technologies, Avricore is playing a critical role
• Avricore has appointed Oak Hill Financial Services Inc. to provide the company with investor relations and advisory services.

When reflecting upon the impact of the COVID-19 pandemic, it is hard to miss the fact that it has accelerated change across the global health care ecosystem. It has made consumers more health-conscious, with many taking more initiative, as evidenced by their willingness to utilize technologies to get information on health issues, as well as track their health and use the data generated to make health-related decisions. They are also accessing and utilizing their medical record data. These new consumer preferences have meant that health delivery organizations (“HDOs”) have had to adapt and innovate within a short time to remain relevant. As a result, HDOs are transforming their care models by including safe, secure, and virtual care delivery, leveraging partnerships, reimagining the workforce, and more. Additionally, the pandemic has exposed the ever-expanding gap between the demand for health care and the supply of resources, including staff, further solidifying the awareness that widespread adoption of digital technologies, such as artificial intelligence (“AI”), cloud computing, and virtual care delivery, is needed to bridge this gap (https://ibn.fm/RwMwL). In this rapidly evolving world of health care, Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF), a health diagnostics technology innovator, is taking part in the digital transformation as well as satisfying emerging consumer preferences through its flagship offering, HealthTab(TM). A turnkey point-of-care testing solution that combines a secure, cloud-based platform with best-in-class point-of-care technologies to help improve the quality of life for patients living with chronic illnesses, HealthTab enables consumers to access important health information conveniently and at a time that is fitting for them. This is especially critical at a time when increasingly health-conscious consumers are looking for these exact technologies and services. “What HealthTab does is it creates a space where a patient can take direct agency over their health,” stated Avricore CEO Hector Bremner (https://ibn.fm/0Bro6). “They can walk into their pharmacy, they can ask that question, and they can get information that they can act on now.” Avricore’s pharmacy-based approach to providing convenient and timely care appears to bode well with the ongoing transformation of the health care system, which has expanded the role of pharmacists. Their responsibilities are evolving to include providing direct care to patients in tandem with physicians through collaborative practice agreements (“CPAs”). Some of these expanded responsibilities include performing patient assessment activities, ordering and interpreting lab tests, creating therapeutic plans, and using initiating, adjusting, or discontinuing drug treatment (https://ibn.fm/8YA9J). In understanding this growing importance of pharmacies and pharmacists, Avricore is using its HealthTab platform to turn the former into community diagnostic centers, enabling pharmacists to seamlessly and successfully take up their expanded responsibilities, thus playing a greater role in primary health services. Avricore has since partnered with Shoppers Drug Mart, which boasts an extensive network across Canada comprising more than 1,300 stores. Following a successful pilot, HealthTab is expected to roll out across more stores, further expanding Avricore’s Canadian coverage. Meanwhile, Avricore announced on September 13 that it had appointed Oak Hill Financial Services Inc., a Toronto-based leading Canadian marketing and distribution firm, to provide investor relations and advisory services. “More specifically, Oak Hill will provide services such as drafting marketing materials and reaching out to its Canadian investor network to expand Avricore’s visibility in the financial community,” explains the announcement (https://ibn.fm/NxucC). For more information, visit the company’s website at www.AvricoreHealth.com. NOTE TO INVESTORS: The latest news and updates relating to AVCRF are available in the company’s newsroom at https://ibn.fm/AVCRF

• The approval by the Marijuana Regulation Agency represents RWB’s authorization to move forward with the operational strategy of its subsidiary RWB Michigan, LLC
• Michigan provides access to a market with approximately 10 million people and a consumer pool responsible for $171 million in sales – resulting in the generation of more than $23 million in tax revenue for the state’s roads, schools, counties, and municipalities
• The Sanderson property in Florida has been built to GMP specifications and is a 4,800 square foot standalone facility that is expected to help bridge the gap and satisfy the fast-growing demand in the cannabis edibles market

Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF), formed when privately held MichiCann Medical Inc. merged with publicly traded Tidal Royalty in 2019, is an innovator of American cannabis – adhering to the highest ethical, manufacturing, education, branding, and employment standards in the industry. The company is a superstate operator, leveraging a sizable footprint to dominate the areas in which it operates. RWB recently announced that it received adult-use (recreational use) prequalification status according to the licensing provisions of the Michigan Regulation and Taxation of Marihuana Act (“MRTMA”) and the associated rules through a wholly owned subsidiary, RWB Michigan, LLC. The approval by the Marijuana Regulatory Agency (“MRA”) represents the authorization of RWB to move forward with the full operational strategy in Michigan and the complete licensing process for the intended facilities (https://ibn.fm/iZYdM). “Michigan provides RWB access to a market with a population of approximately 10 million people, and where, in the month of July, cannabis consumers were responsible for $171 million in sales generating more than $23 million in tax revenue for Michigan’s roads, schools, municipalities, and counties,” CEO and Chairman of RWB, Brad Rogers, said. Michigan is not the only state where RWB is excelling – the company’s Sanderson property in Florida has been built to GMP specifications to capitalize on the growing cannabis derivatives market. The expectation is that the Florida medical cannabis market will reach $1.5 billion in sales during 2021, which marks a growth of 53% over 2020. Medical and recreational use cannabis is expected to be legal in Florida by 2023, with the overall market expected to reach $2.6 billion by 2026 (https://ibn.fm/25uDQ). The Florida facility is a 4,800 square foot standalone structure and is expected to help satisfy the fast-growing demand in the cannabis edibles market. “We are very pleased to have completed this state-of-the-art production facility ahead of time and begin production this month. We will begin with premium specialized confectionary offerings as finished retail-ready packages where medical patients will be able to select from a variety of different products,” RWB’s GM Jim Frazier said. “We are confident this new facility, coupled with our expert staff of edible specialists, can produce a market-leading offering” (https://ibn.fm/RxbUE). RWB enters into strategic brand acquisitions and partnerships that aim to help the company expand its presence and position, with the goal of being a key player in the United States cannabis market. The company is always diligently searching for brands to acquire and bring additional value to expand its footprint. Currently, the company’s brand portfolio consists of Platinum Premium Cannabis Products (“PV”), High Times(R), and Mid-American Growers. Upon completion of RWB’s current proposed investments and acquisitions, the company will be one of the largest companies in the cannabis market. Currently, assets (closed or in closing-stage) are located within Michigan, Illinois, Florida, Oklahoma, Massachusetts, and California. For more information, visit the company’s website at www.RedWhiteBloom.com. NOTE TO INVESTORS: The latest news and updates relating to RWBYF are available in the company’s newsroom at https://ibn.fm/RWBYF

• Although an often unspoken of medical disorder, Hypoactive Sexual Desire Disorder affects approximately 9.5 million women in the U.S. alone
• The project gathers some of the world’s leading researchers in female sexual desire and psychedelics
• This is the first-of-its-kind psychedelic-based treatment program targeting this disorder, with potential global implications
• Clinical trials of MDMA as a treatment for PTSD have shown some success due to targeting the pathways that process fear
• MINDCURE is working with a molecule that will be first-to-market – MDMA is predicted to be approved by 2023 – this brings them closer to the money

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) (“MINDCURE”), a diversified life sciences company currently at the forefront of innovating and improving mental health through the research and use of psychedelic compounds, is pleased to announce the launch of its “Desire Project” to address and treat female Hypoactive Sexual Desire Disorder (“HSDD”) with MDMA-assisted psychotherapy. The Desire Project is the first-of-its-kind study targeting this sexual disorder which affects an estimated 9.5 million premenopausal women in the United States alone. The benefits of the study could potentially impact women and relationships on a worldwide level (https://ibn.fm/uC78c). HSDD is a common sexual disorder characterized by a persistent, low sexual drive with emotional distress that is not associated with an existing medical or relationship problem. According to current estimates, 40% of women in the US have self-reported low sexual desire, with HSDD affecting 10% of adult women and 14% of premenopausal adult women. Men can also suffer from HSDD. “MINDCURE has identified a gap in the market, and I think that with the team we have built to execute this project, we can help those seeking improved desire in a new way. We know that sexual health contributes to overall wellbeing and that studies relating to HSDD suggest that female desire has deep roots in the mind,” MINDCURE President and CEO Kelsey Ramsden said. “Women’s desire issues have not been adequately addressed to date, and we believe that treatment incorporating MDMA and psychotherapy has real promise as it may target those roots of desire in the mind and unlock healing for women lacking desire.” In clinical trials using MDMA, some success has been shown in post-traumatic stress disorder (“PTSD”) patients. The MDMA treatment works on the brain’s pathways related to fear. It can help enhance fear memory extinction, modulate fear memory reconsolidation, and even bolster the social behavior in animal tests. MINDCURE has spent six months planning the upcoming Desire Project with a strong emphasis on how MDMA may ease some of the fear factors in women, which could play a large role in female-related sexual disorders that are not currently treatable by methods or medications on the market. The Desire Project comprises some of the world’s leading researchers in female sexual desire and psychedelics. These world-renowned names include:

• Dr. Anita Clayton (Professor and chair of the Department of Psychiatry and Neurobehavior Sciences and a Professor of Clinical Obstetrics and Gynecology at the University of Virginia), Dr. Jennifer Mitchell (lead author of MAPS MDMA-assisted therapy for PTSD study),
• Dr. Cindy Meston (directs the Female Sexual Psychophysiology Laboratory at the University of Texas in Austin),
• Dr. Robert Pyke (leader of the Addyl project, a drug used to treat the symptoms of HSDD and has author of over 100 peer-reviewed publications in the last 18 years), and
• Dr. Sherry Walling (a practicing, licensed clinical psychologist with a master’s degree in theology and emphasis on trauma).

“During my decades as a psychiatrist, I’ve seen first-hand the limitations of existing treatments. This is an exciting opportunity to find a potentially more effective and better tolerated treatment for women affected by this disorder,” Mind Cure Health CMO Dr. Joel Raskin, MD, said (https://ibn.fm/4MJOp). Living with HSDD can damage the lives of the women it affects, causing depression and anxiety – potentially destroying personal relationships. Through the Desire Project, MINDCURE hopes to tackle the challenges faced by women suffering from this disorder. For more information, visit the company’s website at www.MindCure.com. NOTE TO INVESTORS: The latest news and updates relating to MCURF are available in the company’s newsroom at http://ibn.fm/MCURF

• What: USA CBD Expo 2021
• When: October 28-30, 2021
• Where: Chicago, Illinois
• Details on the Venue: Hosted at the famous McCormick Place convention center in downtown Chicago
• Key Stats: 50+ field experts, 300 unique vendors, and thousands of high-quality products from all over the globe

The skyrocketing global CBD and hemp markets have only continued to dominate the industry after the COVID-19 pandemic. Now, professionals from around the world can finally come together to discuss the knowledge, experience and advice they’ve acquired this past year at the USA CBD Expo 2021 in Chicago, Illinois. The event is hosted from October 28-30 at the famous McCormick Place convention center and is considered the largest CBD expo series in the nation. The massive 2 billion dollar venue space and recent advances for cannabis legalization in Chicago makes it the perfect setting for this global CBD showcase (https://ibn.fm/1AoKh). The windy city also hosts massive market potential for the CBD and hemp industry due to foot traffic alone, as more than 58 million travelers visit the windy city each year. Additionally, since its legalization, retail cannabis sales within the state have skyrocketed to an estimated $40 million in revenue. In addition to the city’s impressive statistics, the convention center is conveniently located near several luxury lodgings already blocked out for the event, like the Hilton Garden Inn and Home2 Suites. The convention’s presentation sponsor, 3Chi, stays at the forefront of this booming industry by creating a professional gathering for experts and business owners from various fields of CBD and hemp. The American-made company prides itself on its biochemist formulated and lab-tested hemp products. Their impressive list of participants includes more than 50 experts in the CBD and hemp field and hundreds of unique vendors displaying thousands of high-quality products. The scheduled talks range from marketing and finance to niche topics like sports medicine, sustainability, farming, and even animal medicine. Some of the highly anticipated talks include actor Jason Gann from Wilfred Hemp & CBD and Wilfred Cannabis, Scott Frohman and The Power of Medicinal Mushroom Extracts, as well as discussions surrounding delta-8, psychedelic education, and CBD for sexual wellness. Four possible ticket types are available for the convention, ranging from Industry Buyer and Industry Professional passes to General Admission and Press passes. Each ticket type has applicable perks and most choices encompass the entire three-day event to professional networking opportunities. Additionally, vendors may receive a discount if they sign up for multiple days of the event. Tickets for the Chicago showcase are available for purchase on the event’s website (https://ibn.fm/FeBYp). For further information about USA CBD Expo 2021 or to learn how to buy tickets, visit the event’s website at https://usacbdexpo.com

• Plant-based food retailer and community builder PlantX Life Inc. is tapping into a growing consumer market focused on health and longevity, providing education and other resources to help make plant-based community goals more accessible
• PlantX Life maintains a digital presence that includes a weekly podcast series, YouTube channel videos, an informative blog and an e-commerce portal accessible through Walmart’s and Amazon’s Marketplace
• The company is preparing to open a store and affiliated website in United States in October and Israel in November to add to its brick-and-mortar presence in Canada     PlantX Life sells over 5,000 products and eventually expects to consistently add new       items and brands to its offerings

One-stop shopping plant community brand builder PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) continues to passionately pursue its mission not only through a growing retail presence, but by establishing an ecosystem that preaches the virtues of plant-based living and the increasingly supportive community arising from common plant lifestyle interests as well. PlantX’s vodcast series provides weekly insights into vegan products, athletes who thrive on a plant-based diet, and industry trends. With season 2 well under way, the “vodcast” recently featured interviews with tennis star Venus Williams and Two Bears co-founder David Schneiderman, whose company sells oat milk lattés, coffee, and oat milk (https://ibn.fm/XvYdC). Through its YouTube channel (https://ibn.fm/56AsQ). PlantX provides upbeat how-to videos for recipes and fitness practices, as well as news about the state of the industry and PlantX’s investor relations. And the company’s blog provides the mortar for binding PlantX’s community of vegan lifestyle interests together with education to make consistency in beneficial habits more accessible (https://ibn.fm/PULUB). “Over the last 10 years I’ve learned that a plant-based diet is a major part of wellness and longevity,” PlantX founder Sean Dollinger said in a video shared this summer about his journey toward a healthier lifestyle. “Don’t feel like you have enough time to prepare healthy food? We’ll deliver plant-based meals right to your door. But it’s not all about food. There are health benefits of having plants in your home and they’re great for home decor and gifts. We also want to help you find the best plant-based restaurants, interact with others in the plant-based community, share ideas and grow together.” As the digital hub of a thriving plant-based market ecosystem, the company sells more than 5,000 plant-based products across North America and anticipates an ongoing expansion of its product lines. In September, PlantX announced a number of initiatives that will expand awareness of its profile. The company will launch as a seller on Amazon Marketplace (https://ibn.fm/Iy9m7) and on Walmart’s Marketplace in the United States after a successful entry on the Walmart Marketplace in Canada (https://ibn.fm/plRwx). The company has already opened a brick-and-mortar store in Squamish, British Columbia, and will open additional physical stores in San Diego in October, and Tel Aviv in November. Additionally, the company will launch an Israel-based website in conjunction with its store there. All of the company’s physical stores will be rebranded as XMarket (https://ibn.fm/wc66z). “We’re here as a resource and hopefully we can give you a healthier and longer life. You can’t put a price tag on that,” Dollinger said. For more information, visit the company’s websites at www.PlantX.com, www.PlantX.ca, and https://investor.plantx.com/ and view PlantX for Plant-Based Investors. NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF

Thursday- October 21, 2021 Venue- Wyndham Grand Hotel, Jupiter, FL The Dawson James Securities’ 6th Annual Small Cap Growth Conference is being held on October 21st 2021 at the scenic Wyndham Grand Hotel, Jupiter, Florida. Small-cap industries, company executives, and investors from the healthcare, technology and consumer sectors are invited to attend this Small Cap Growth Conference. There is no fee for attendees. Since 2004, Dawson James Securities, an investment banking firm with offices in New York, Florida and Maryland has propelled small and microcap public and private growth companies towards growth and lucrative investment opportunities. This 6th annual Small-cap growth conference is focused on providing a unified platform for senior leadership from approximately 40 small-cap growth companies and 12 leading industry sponsors to communicate and develop productive business relationships with institutional funds, family offices and high net-worth investors. The event will feature keynotes and discussions from industry leaders and accredited investors about the trends and the future of investment and growth in the small-cap industries of the healthcare, consumer, and technology segment. 40 participating companies will be  showcased on the 21st with a 2-track presentation format about the nature and prospect of their business and potential benefits of association. Dawson James Securities organizes these conferences for the benefit of small and microcap industries. The format allows potential investors to hear the presenting companies’ stories first hand and to interact directly with senior leadership teams.  This conference specifically targets small and microcap industries that seek exposure and better investment opportunities. Entrepreneurs, startups, and small industries can leverage this conference platform to reach out to investment firms and get discovered by distinguished sponsors to develop long-term networking and business alliances. The event will commence with registration and breakfast promptly at 8:00 a.m. on Thursday, Oct. 21, 2021, followed by corporate presentations, discussions from industry leaders, and one-on-one management meetings. To know more about the event https://ibn.fm/GlnPH.

• Lexaria Bioscience is the global innovator behind the disruptive DehydraTECH(TM) drug delivery technology
• DehydraTECH’s taste-masking capabilities eliminate the need for unwanted sweeteners or chemical masking agents
• The technology also significantly increases the bioavailability of drugs, speeds up the rate of drug onset, and boosts brain absorption
• DehydraTECH presents numerous opportunities and has been evaluated in R&D programs featuring DehydraTECH-processed nicotine, antivirals, and cannabidiol

Oral delivery is the easiest and most convenient way to administer medications, yet it is prevalently associated with patient noncompliance owing to many drugs’ bitter taste. The problem appears widespread and necessitating remedial bitterness-masking interventions. But as recently as 2013 (relative to the mid-19th century origin of the modern pharmaceutical industry), the taste-masking of oral solid dosage forms was still a major challenge that needed to be addressed by formulation or pharmaceutical scientists (https://ibn.fm/7wmaW). The most commonly used taste-masking methods at that time were film coating and the use of sweeteners, sugars, or flavors, but the latter is considered ineffective due to its inability to adequately mask the bitter taste. Still, less conventional methods such as microencapsulation, spray drying, supercritical fluids, and more had already been reported as successful taste-masking techniques. Since then, Lexaria Bioscience (NASDAQ: LEXX), a global innovator whose patented DehydraTECH(TM) drug delivery technology could potentially improve oral administration of Active Pharmaceutical Ingredients (“APIs”), has led the pharmaceutical industry in advancing novel taste-masking techniques. With part of its R&D having progressed from animal studies to human clinical studies, the company has so far established that DehydraTECH masks unwanted taste, thereby eliminating the need for sugar-filled edibles; improves the speed of drug onset; increases the effectiveness of drug delivery into the bloodstream (bioavailability); and boosts brain absorption (https://ibn.fm/la1J9). DehydraTECH’s taste-masking capabilities result from the use of fatty acids. The technology combines the API with fatty acids, such as long-chain fatty acid (“LCFA”), before applying the resultant compound to food/carrier particles (substrate material), performing dehydration synthesis procedure, and, finally, rendering it as powder or liquid for use in desired final form factor. Importantly, according to an evaluation LEXX conducted in collaboration with National Research Council, the largest R&D organization in Canada, DehydraTECH does not alter the chemical structure of the API. The fatty acids offer dual benefits. First, they are believed to block and divert bound APIs away from bitter taste receptors, essentially rendering them flavorless, as well as odorless. “DehydraTECH formulations do not require unwanted sweeteners or chemical masking agents for flavor and odor blocking, allowing manufacturers to create low-sugar products with fewer calories, while also avoiding the use of excessive artificial sweeteners,” reads the company’s website (https://ibn.fm/TfY0x). The LCFA also promotes quick absorption into lymphatics, bypassing the first-pass liver effect, which drastically reduces the bioavailability or overall effectiveness of orally ingested drugs. In this regard and based on findings of clinical testing, DehydraTECH significantly increases bioavailability for fat-soluble drugs. DehydraTECH has so far been evaluated as part of nicotine, antivirals, and cannabinoids (“CBD”) R&D programs. The nicotine program showed that the drug delivery platform significantly increased the quantity of nicotine delivered. It was also responsible for 295% higher brain levels of nicotine compared to controls. Additionally, its first 2021 human clinical study under the CBD program, HYPER-H21-1, has evidenced a rapid and sustained decline in blood pressure, with the reduction being more pronounced in the first 10 to 50 minutes of the study. The second 2021 human clinical study, HYPER-H21-2, has demonstrated up to 23% drop in blood pressure with DehydraTECH-CBD compared with placebo. Though Lexaria still awaits additional analyses, its drug delivery technology has proven useful for potentially treating hypertension. Thirdly, its antiviral program, featuring cell-based and animal studies using Remdesivir and antiviral drugs being investigated for SARS-CoV-2 and HIV/AIDS, has demonstrated enhanced drug delivery. Since it began developing DehydraTECH in 2014, Lexaria has significantly strengthened and broadened the technology to an unprecedented degree. Even so, more may still be in the offing for the company currently disrupting the pharmaceutical industry. For more information, visit the company’s website at www.LexariaBioscience.com. NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Tryp Therapeutics on September 22 submitted an IND application to the FDA to evaluate its oral formulation of synthetic psilocybin, TRP-8802, in a Phase 2a clinical study
• The study seeks to evaluate TRP-8802 for the treatment of patients with eating disorders and will enroll 10 patients
• According to Tryp Chairman and CEO, the submission is the first of several IND filings the company intends to make in the coming months
• Tryp is also preparing for Phase 2b clinical trials, which will evaluate its proprietary drug candidate, TRP-8803

During a recent investor presentation, Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a pharmaceutical company focused on developing novel bioscience solutions for conditions with high unmet need, expressed its expectation to initiate at least two Phase 2a clinical trials in Q4 2021 (https://ibn.fm/H85KV). The trials, to be conducted at the University of Florida under the guidance of Dr. Jennifer Miller, a pediatric eating disorders expert and the trials’ principal investigator, will evaluate TRP-8802, Tryp’s oral formulation of synthetic psilocybin, in combination with psychotherapy. The company announced September 22 that it had submitted to the US Food and Drug Administration (“FDA”) an Investigational New Drug (“IND”) application to evaluate TRP-8802 in the Phase 2a study for the treatment of patients with eating disorders (https://ibn.fm/ze4vd), acting as its first major clinical development milestone. According to Dr. Miller, the submission represents hundreds of hours of preparation, design, and coordination as Tryp and its partners “pursue a leading-edge treatment of psilocybin with psychotherapy.” Part of the efforts Dr. Miller was alluding to include collaborations with Clinlogix, a contract research organization (“CRO”), the University of Florida, and Fluence, a psychedelic therapy educational platform. In late August, Fluence undertook and completed the training of psychotherapists who will take part in the trial by overseeing dosing sessions (https://ibn.fm/7G3Ri). On its part, Clinlogix will support the upcoming Phase 2a clinical trials by providing medical writing, biostatistical analysis, data management, and trial monitoring (https://ibn.fm/BP4YW). The submission sets the stage for the Phase 2a clinical trial subject to a favorable review by the FDA. The study is expected to enroll 10 patients with various overeating disorders, such as hypothalamic obesity, binge eating disorder, and Prader-Willi Syndrome. The administration of TRP-8802 is expected to enhance neuroplasticity and help create healthy neural patterns associated with hunger and eating. Prior to the administration, the patients will meet with the trained psychotherapists for two sessions. The psilocybin will then be administered during two drug-dosing sessions, after which integration sessions will follow. “This IND submission marks the most important milestone the company has achieved to date and will be critical in identifying patient responses to the active ingredient, consistent with that of our proprietary drug candidate, TRP-8803, that will be used in Phase 2b trials and beyond,” said Tryp Chairman and CEO Greg McKee. McKee also noted that the submission is the first of several IND filings the company expects to make in the coming months, further reiterating that Tryp is eager to begin enrolling its first patients in multiple Phase 2a trials later this year. For Tryp, this is only the beginning. The company intends to use TRP-8803, its proprietary psilocybin-based drug product manufactured exclusively for Tryp, for Phase 2b clinical trials, and beyond. It has already announced partnerships with the University of Michigan, Calvert Labs, and Gad Consulting to conduct bridging studies in preparation for Phase 2b clinical trials, with more collaborations possibly still in the works. In this regard, the clock has begun counting what will likely be hundreds of additional hours of preparation, design, and coordination in readiness for the Phase 2b trials. For more information, visit the company’s website at www.TrypTherapeutics.com. NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF

• FingerMotion Inc., has become a provider for China’s booming e-commerce market with rich communication services (“RCS”) and big-data insights, developing its Sapientus database as a solution for clients’ predictive services needs
• In addition to its SMS, MMS and mobile top-up business, FingerMotion’s focus on adapting Sapientus to the needs of the insurance industry are driving revenues to new records each quarter
• In China, insurance is compulsory to protect certain societal needs, such as pensions, medical care, employment (and unemployment), and maternity care, creating a ready market for insurance providers
• The Sapientus platform creates proprietary matrices for assessing consumer risk potential using context-based outlooks in accordance with established behaviors

The development of business capabilities to harvest and apply big data insights is affecting revenue streams that vary in size and impact from national government contractors (https://ibn.fm/yE6s6) to farmers harvesting their fields (https://ibn.fm/Vqw3t). Industry e-magazine Datamation reported Sept. 26 on Splunk findings that “organizations with ‘mature data practices’ release twice as many products and increase employee productivity at double the rate of organizations with less mature data practices” (https://ibn.fm/kQuHI). Big data communications technology innovator FingerMotion (OTCQX: FNGR) is focusing its new platform on China’s insurance market as the nation serving as the home to some 1.4 billion people continues to build a powerful economy on the efforts of factories crucial to the global supply chain. FingerMotion launched its Big Data Insights division with its flagship database IP Sapientus last year and attracted global insurance behemoth Pacific Life Re-insurance as a client interested in developing a customer base within China. Sapientus is a stand-out technology that applies publicly available data to clients’ risk forecast needs, generating proprietary matrices that assimilate information on individuals’ behaviors to create context-based outlooks for customers. It’s a service that’s particularly attractive in China since the country’s credit and insurance risk standards are still in a developmental stage and Sapientus can help provide an alternative means of judging potential liabilities for a corporate client. During the past year, FingerMotion’s revenues have seen steady growth, largely due to mobile communications services, and the Pacific Life agreement earlier this year positioned it for an even more promising future.  CEO Martin Shen said during a corporate update conference call discussing the company’s first-quarter financial results in August that FingerMotion’s top-up business had risen 341 percent and mobile SMS and MMS services had increased by 77 percent, and that “some significant funds” raised after the quarter ended will likely lead to a higher outcome on the balance sheet once the Q2 report is completed. “Most of the e-commerce companies operate in the red for quite a while before they turn a profit, but our current trajectory has us moving in that profitable direction a bit quicker than maybe other companies have been,” Shen said (https://ibn.fm/OPdc3). Shen acknowledged that the company has considered eventually focusing its big data platform on other industries beyond insurance and in markets beyond China’s borders, but said the company needs to stay focused on its immediate purpose before expanding its reach. “We’ve always thought of the ability of the algorithms that we have. It’s not really just to perfect those algorithms but it’s also to have them exportable and replicated in other jurisdictions, in other markets. … But again, that takes time to develop, and we’re really still developing what we’re doing right now in China,” Shen said. “Right now, let’s just build and make sure that our foundation is strong first.” For more information, visit the company’s website at www.FingerMotion.com. NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

• Some social media platforms, like TikTok, pay artists for their music, but the amounts are insignificant, and an artist’s musical track would have to be used hundreds of thousands of times to make a decent profit
• Friendable’s Fan Pass Live provides artists an online platform to share their music content and earn a profit
• Artists earn on Fan Pass through fan subscriptions, merchandise sales, ticket sales, and more
• Fan Pass artists have access to Pro Services that include logo design and merchandise, as well as social media promotions for upcoming events

2020 was a year of change (and growth) for the music industry. Streaming replaced in-person shows, and artists were forced to adapt and evolve to stake a piece of the revenue. Fast-forwarding to today, live streaming shows and other events are the new normal. More and more artists are entering the virtual stage without representation, simply going online to do what they love and earn money in the process. Artists don’t have to rely solely on social media platforms like TikTok, with revenue structures that constantly change, to gain recognition for their craft. For example, TikTok does pay its artists revenue, but it is based on the number of times their song is used to make a video. Each time the track is used to create a video, it is considered a “creation,” the metric value in which TikTok measures popularity for revenue purposes. To make a living off of TikTok alone, artists would need to secure hundreds of thousands of creations each month (https://ibn.fm/lRrAB). A more attractive and lucrative revenue-generating option available for up-and-coming artists is the Fan Pass platform, launched in July 2020 by Friendable (OTC: FDBL). On the Fan Pass streaming artist platform, artists can build up a fan base, gain access to merchandising, and earn revenue while doing what they love. Each artist has the opportunity to earn revenue from the monthly subscription fee that fans pay to gain access to the Fan Pass artist catalog, merchandise purchases, and even 100% of ticket sales for exclusive live-streamed content and videos on-demand. Artists also have access to premium equipment available for purchase and exclusive Artist Pro Services. The Artist Pro Services are offered in three tiers – basic, standard, and a premium-style option. Each is priced accordingly and offers artists options for logo design, merchandise designs, and marketing material. The process is easy to get started. Artists fill out a form answering survey questions, the prototype is created, and artists then communicate what they like, don’t like, or want to be changed. Packages are even available for social media promotion of upcoming events. Prices range from $45 for a social ad/announcement design to promote the next three events to a $400 pro merch collection with five high-resolution designs placed in the store on any five merchandise items available. Friendable is currently implementing a 120-day plan that strategizes growth for the Fan Pass platform. The company has already accomplished creating and releasing version 2.0 of the platform, gaining acceptance from the Apple Store and Google Play Store for the new application, and launching a brand awareness campaign, among others. Additionally, Fan Pass has begun promoting Pro Services to help artists receive revenue for doing what they love. With this approach and the wealth of services and benefits available, Fan Pass is in a unique position to disrupt the music streaming market, an expanding sector that is growing in value from $20.6 billion in 2019 to an anticipated $60.5 billion by 2026 (marking a CAGR of 16%). The immediate increase for this market segment is due to the increased availability of the internet and access to online content through services like Fan Pass (https://ibn.fm/gw0Vq). For more information, visit the company’s websites at www.Friendable.com or www.FanPassLive.com. NOTE TO INVESTORS: The latest news and updates relating to FDBL are available in the company’s newsroom at http://ibn.fm/FDBL